Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
Wellgistics Health, Inc. files its annual report describing a fast‑growing healthcare ecosystem built around specialty‑lite pharmaceuticals, wholesale distribution and a digital pharmacy hub. The company operates through Wellgistics Pharmacy, wholesale unit Wellgistics LLC, technology platform DelivMeds and holding entity Wood Sage.
Wellgistics closed the Wellgistics LLC acquisition on August 30, 2024, with consideration including a $10 million closing cash payment, a $15 million promissory note and equity‑based bonuses, later restructured into 3,999,335 restricted shares. The cash payment is now due the earlier of 120 days after its Form S‑1 becomes effective or August 30, 2025. The report highlights its 5P‑Model serving patients, providers, pharmacies, payors and manufacturers, and lists extensive risk factors around integration, reimbursement pressure, competition, regulation, debt and technology reliance.
Wellgistics Health, Inc. entered a three-year Interim Commercialization and Revenue Share Agreement with Kare PharmTech to market, promote and distribute Kare’s KARE Verify eligibility and benefits verification product through Wellgistics’ pharmacy and distribution network.
All net revenue from KARE Verify will be split 50% to Wellgistics and 50% to Kare PharmTech. Wellgistics also secured preferred pricing for medical insurance eligibility and benefits verification services, which it plans to offer immediately via its EinsteinRx AI hub and later integrate into its PharmacyChain platform to support a new revenue stream starting in the second quarter of 2026. The EBV market is cited as growing from $2.39 billion in 2025 to $3 billion in 2030.
Wellgistics Health, Inc. filed a current report highlighting the launch of Forzet™, a medical food for the dietary management of muscle loss associated with weight loss therapies, including GLP-1 agonist drugs such as Ozempic, Wegovy and Mounjaro.
Forzet is classified as a medical food, is available over the counter, does not require a prescription, and is intended for use under physician supervision. It has been evaluated in multiple controlled clinical studies, including in patients with Type 2 diabetes, heart failure and COPD in Europe.
Wellgistics plans to recommend Forzet through its EinsteinRx AI pharmacy hub via point-of-sale pop-ups in its 6,500+ pharmacy network and to feature GLP-1 drugs and Forzet in its growing direct-to-consumer and telehealth offerings. The press release notes estimates that the GLP-1 agonist market could grow from $70 billion in 2025 to $201 billion in 2030.
Wellgistics Health, Inc. entered a court-approved settlement with Silverback Capital Corporation to resolve at least $10,712,734.16 of company liabilities through the issuance of common stock under a Section 3(a)(10) exemption. A Florida court approved the fairness of both the settlement terms and related share issuances.
The settlement allows shares to be issued in tranches by dividing portions of the claim amount by fixed prices between $0.25 and $2.25 per share, with the first $2,250,000 tranche set at $0.25 per share. Wellgistics also agreed to issue 100,000 shares as a settlement fee and 300,000 shares for legal fees. Separately, the company appointed Fortitude Advisors, owned and controlled by Gerald Commissiong, as consulting Chief Business Officer, and announced an expanded partnership with Tollo Health’s TolloCare unit to add GLP-1 and Long COVID telehealth services and a mental health AI app to its platform.
Wellgistics Health, Inc. elected Gary Herman as an independent director effective February 4, 2026, and named him chairman of the Audit Committee. Non‑employee directors receive a $120,000 annual cash retainer, an annual equity award of 60,000 shares of Common Stock, and 200,000 restricted shares vesting over three years at appointment.
The company also entered into an agreement with NFL Alumni Health to develop healthcare and wellness programs using its EinsteinRx AI pharmacy hub and PharmacyChain blockchain platform. The programs will start with former NFL players, then expand to rural communities through a network of more than 6,500 independent pharmacies, focusing on mental health, weight loss, sleep apnea, cardiometabolic disease, pain management, and Long COVID.
Wellgistics Health, Inc. reported that two members of its board of directors resigned effective February 1, 2026. Steven Lee resigned from the board and his role on the Ethics Committee, and Howard Doss resigned from the board and his role as chairman of the Audit Committee.
Both directors stated that their decisions to step down were not the result of any disagreement with the company regarding its operations, policies, or practices. The company also filed their formal resignation letters as exhibits to this report.
Wellgistics Health, Inc. entered into a private offering of secured convertible promissory notes with certain investors, agreeing to issue up to $8,125,000 in aggregate principal amount for an aggregate purchase price of $6,500,000, reflecting a 20% original issue discount. The notes mature on the earlier of six months from issuance or the closing of a Qualified Financing and carry a 0% interest rate unless an event of default occurs, when the rate increases to 18% per annum.
Holders may elect to convert outstanding amounts into common stock at a conversion price of $0.4057 per share. The notes are guaranteed by a subsidiary and secured by the assets of the company and its wholly owned subsidiaries under a security agreement and an intellectual property security agreement. While the aggregate principal amount remains outstanding, the company is restricted from incurring new borrowed money or new liens other than on its intellectual property, and investors receive rights to participate in future offerings. Wellgistics engaged Dawson James Securities, Inc. as placement agent, paying a 6.5% selling commission on gross proceeds and issuing warrants equal to 5% of the aggregate gross proceeds, with an exercise price set at the common stock’s closing price before the offering closed.
Wellgistics Health, Inc. entered into a note purchase agreement to issue and sell up to $3,125,000 in aggregate principal amount of convertible promissory notes in a private offering, for an aggregate purchase price of $2,500,000 reflecting a 20% original issue discount. The notes carry 0% interest unless a default occurs, when the rate increases to 18% per year, and mature on the earlier of six months after issuance or the closing of a qualified financing of at least $2,000,000. Holders may elect to convert outstanding amounts into the equity securities sold in such a qualified financing, at the financing price but not below a floor price of $0.08 per share, which was set to avoid issuing more than 20% of the company’s capitalization. A subsidiary guarantees all amounts due, investors receive participation rights in future offerings up to 100% of their note principal, and the company agreed to restrictions on incurring additional debt or new liens while the notes remain outstanding. Wellgistics paid $162,500 in selling commissions and issued placement agent warrants equal to 5% of gross offering proceeds to Dawson James Securities, Inc.
Wellgistics Health, Inc. reports that it received a notice from Nasdaq on December 10, 2025 stating that its common stock failed to meet the minimum closing bid price of $1.00 per share for 30 consecutive business days through December 9, 2025, as required under Nasdaq Listing Rule 5550(a)(2).
Nasdaq has granted an initial compliance period until June 8, 2026 for the company to regain compliance, with the possibility of an additional 180-day period if other listing standards are met and a reverse stock split is used if necessary. The shares will continue trading on The Nasdaq Capital Market under the symbol WGRX for now, but the company notes that its stock could be delisted if bid price compliance is not restored.
Wellgistics Health, Inc. filed a current report stating that on December 4, 2025 it issued a press release, which is furnished as Exhibit 99.1. The company classifies this information under Regulation FD, meaning it is being shared to keep public disclosure consistent and broad. The exhibit is expressly described as furnished, not filed, so it is not subject to certain liability provisions and is not automatically incorporated into other SEC filings.
The report also highlights that the press release contains forward-looking statements about projects, potential financial performance, and growth opportunities. These statements are subject to risks and uncertainties described in the company’s SEC filings, including its Registration Statement on Form S-1 that was declared effective on September 25, 2025. Wellgistics notes it has no obligation to update these forward-looking statements after the date of the press release.